Login / Signup

Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.

Ken LiuJonggi ChoiAn LeTerry Cheuk-Fung YipVincent Wai-Sun WongStephen Lam ChanHenry Lik Yuen ChanMindie H NguyenYoung Suk LimGrace Lai-Hung Wong
Published in: Alimentary pharmacology & therapeutics (2019)
Compared to untreated patients, TDF treatment reduces the risks of HCC, hepatic decompensation and death in CHB patients with cirrhosis at 5 years.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • hepatitis b virus
  • peritoneal dialysis
  • prognostic factors
  • antiretroviral therapy
  • human health
  • smoking cessation